For patients with unresectable hepatocellular carcinoma (HCC), combining Nexavar (sorafenib) with transarterial chemoembolization (TACE) appears to improve outcomes compared to the use of TACE alone. These results were presented recently at the Gastrointestinal Cancers Symposium (GICS) 2018.
Liver cancer, or hepatocellular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide.1,2 The prognosis for patients with advanced liver cancer is poor,2 and the multikinase inhibitor, Nexaver, has been the only approved treatment, until the recent approval of Stirvaga.3,4
For this clinical trial, researchers randomly assigned 156 patients with unresectable HCC to be treated with TACE, or Nexavar plus TACE, and directly compared the outcomes. Treatment continued until time to untreatable progression (TTUP), when TACE was no longer possible owing to untreatable tumor progression, deterioration to, or the occurrence of vascular invasion and/or extrahepatic spread.
The duration of overall survival without cancer progression was significantly longer; 25.2 months for patients who received combination treatment as compared to 13.5 months for those treated with TACE alone.
Overall survival was not reached at the time of this analysis, and the overall impact of the combined approach will be presented at a future meeting, when the events reach the targeted numbers.
The study authors stated “clearly show that TACE in combination with Nexavar is a treatment option that improves clinical outcomes and may be a new standard treatment for patients with intermediate-stage HCC
- Gastrointestinal Cancers Symposium (GICS) 2018. Abstract 206, presented January 19, 2018.
- 1 World Health Organization. Cancer. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed: April 2017.
- 2 World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Last accessed: April 2017.